A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of Age

Varicella Clinical Trial

Official title:

A Single-center, Randomized, Double-blind Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of Age

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05839301
• Other study ID #: CNBG-BIBP-VZV-08
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: April 27, 2023
• Est. completion date: April 30, 2024

Study information

• Verified date: June 2023
• Source: China National Biotec Group Company Limited
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to evaluate the lot-to-lot consistency, immunogenicity, and safety of live attenuated varicella vaccine manufactured by Beijing Institute of Biological Products Co., Ltd in healthy children.

Description:

This trial is aim to evaluate the lot-to-lot consistency, immunogenicity, and safety of live attenuated varicella vaccine manufactured by Beijing Institute of Biological Products Co., Ltd in healthy people 1 to 12 years of age.1200 healthy subjects aged 1-12 years were enrolled after their guardians passed the informed consent, inclusion and exclusion criteria screening in turn. Three batches were randomized in a 1:1: 1 ratio, with 400 subjects in each batch.All subjects received 1 dose of trial vaccine (Batch 1 or Batch 2 or Batch 3) and all were collected Blood samples were collected from subjects before vaccination, on Day 30 after vaccination for serum neutralizing antibody testing to evaluate immunogenicity, and Safety observations were performed until 6 months post-vaccination in all subjects.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 1200
• Est. completion date: April 30, 2024
• Est. primary completion date: July 30, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 1 Year to 12 Years

Eligibility

Inclusion Criteria:

• Age 1 to 12 years on the day of enrollment ,male or female, and able to provide legal identity certificate.

• Subjects and/or guardians have the ability to understand the study requirements and process, agree to participate in the clinical trial and sign the informed consent form.

• Axillary temperature = 37.0 ° C on the day of enrollment.

Exclusion Criteria:

• Previous vaccination against varicella (eg, varicella vaccine, measles + varicella vaccine).

• History of varicella or herpes zoster infection, or exposure to varicella/herpes zoster within 30 days of enrollment or suspected varicella/herpes zoster;

• Current use of salicylates (including salicylic acid, aspirin, diflunisal, p-aminosalicylic acid (sodium), salsalsalate, benorilate, etc.), or planned long-term use during the study.

• Febrile illness (axillary temperature = 38.5 ° C) or use of antipyretic, analgesic, and anti-allergic drugs (eg, acetaminophen, ibuprofen, aspirin, loratadine, cetirizine, etc.) 3 days before vaccination.

• History of allergy to vaccine ingredients and excipients or severe drug allergy, such as anaphylactic shock, allergic laryngeal edema, Henoch-Schonlein purpura, thrombocytopenic purpura, local allergic necrosis reaction (Arthus reaction), severe urticaria.

• History of epilepsy, convulsions, or convulsions, or a family history of psychosis.

• Impaired immune function or has been diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune diseases.

• Patients suffering from serious congenital malformations, genetic diseases, serious cardiovascular diseases, serious liver/kidney diseases, diabetes with complications, malignant tumors, severe malnutrition.

• Immunosuppressant therapy such as chronic oral or injectable glucocorticoid therapy (= 14 days at doses = 2 mg/kg/day or = 20 mg/day prednisone or equivalent prednisone dose) within 3 months prior to administration of trial vaccine or planned 30 days following administration, but not limited by topical use (eg, ointment, eye drops, inhalers, or nasal sprays).

• Receiving blood/blood-related products or immunoglobulins 3 months before vaccination or planning to use such products 30 days after vaccination.

• Vaccination with a live attenuated vaccine within 30 days or any vaccine within 14 days prior to vaccination.

• Absence of spleen or splenectomy due to any condition such as splenectomy.

• Patients with a history of thrombocytopenia or other coagulation disorders, which may cause contraindications to subcutaneous injection.

• Infectious, suppurative and allergic skin diseases.

• Participating in other investigational or non-registered product (drug, vaccine or device, etc.) clinical trials, or planning to participate in other clinical trials before the end of this clinical trial.

• Subject has any other factor that, in the judgment of the investigator, would make the subject unsuitable for participation in the clinical trial.

Related Conditions & MeSH terms

• Chickenpox
• Herpes Zoster
• Varicella

Intervention

Biological:
• Investigational live attenuated varicella vaccine (lot 1)
0.5ml/vial
• Investigational live attenuated varicella vaccine (lot 2)
0.5ml/vial
• Investigational live attenuated varicella vaccine (lot 3)
0.5ml/vial

Locations

Country	Name	City	State
China	Xinyi Center for Disease Control and Prevention	Xuzhou	Jiangsu

Sponsors (3)

Lead Sponsor	Collaborator
China National Biotec Group Company Limited	Beijing Institute of Biological Products Co Ltd., Jiangsu Province Center for Disease Control and Prevention

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Geometric mean titers (GMT) of anti-VZV neutralizing antibodies	Geometric mean titers (GMT) of anti-VZV neutralizing antibodies 30 days after vaccination in the negative population before immunization	30 days after vaccination
Secondary	Positive conversion rate and geometric mean fold increase (GMFI) of anti-VZV neutralizing antibodies	Positive conversion rate and geometric mean fold increase (GMFI) of anti-VZV neutralizing antibodies 30 days after vaccination in the negative population before immunization	30 days after vaccination
Secondary	Positive conversion rate, GMT, and GMFI of anti-VZV neutralizing antibodies	Positive conversion rate, GMT, and GMFI of anti-VZV neutralizing antibodies 30 days after vaccination in the whole population	30 days after vaccination
Secondary	The incidences of adverse events (AEs)	AEs occurred witnin 30 days after vaccination will be collected	30 days after vaccination
Secondary	The incidences of serious adverse events (SAEs) and Adverse Event of Special Interest(AESI)	SAEs and AESI occurred witnin 6 months after vaccination will be collected	6 months after vaccination